Jefferies upgrades Chemed stock rating on hospice growth, margin gains
Jefferies upgraded Chemed (CHE) to Buy with a $620 price target, citing growth in its hospice business and margin gains. The firm expects earnings stability and valuation expansion. Chemed's Q2 earnings beat estimates, with adjusted EPS of $6.06 and revenue of $673.25M. UBS also initiated coverage with a Buy rating and $650 target, projecting strong EPS growth.
How this was made
The 30-second read
Why it matters
The combined analyst upgrades reinforce a bullish narrative for CHE, potentially attracting new buying interest.
Market read
The fresh upgrades provide a clear catalyst for CHE, likely prompting short-term buying pressure.
What to watch
Potential regulatory changes in hospice reimbursement and the lingering earnings volatility from Roto-Rooter.
Background
Jefferies' upgrade follows Chemed's recent Q2 earnings beat and UBS initiating coverage with a higher price target.
Ticker impact
Jefferies upgraded Chemed to Buy and raised the price target to $620, citing hospice growth and margin improvements.
likely upward pressure as investors price in the new buy rating and higher target.
The upgrade is a fresh, material analyst action with specific valuation numbers, providing a clear trading catalyst.
Market effects
Positive outlook for hospice and home health services may lift peers in the senior care sector.
U.S. healthcare stocks could see modest gains as the upgrade highlights sector stability.
Limited to U.S. markets; no direct global impact.
Counterpoint
Some investors may question the sustainability of hospice margin expansion and view the upgrade as premature.
Key entities
- analystJefferies
Upgraded CHE to Buy and raised price target to $620.
- analystUBS
Initiated coverage with a Buy rating and $650 price target.
